Erasca Cash Flow Statement
NASDAQ: ERASHealth CareBiotechnology: Pharmaceutical PreparationsUSD
16.03+0.57 (+3.69%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Erasca free cash flow
In fiscal 2025, Erasca generated -$95.5 million of operating cash flow and spent $128,000 on capital expenditures. That left free cash flow of -$95.6 million.
Summary generated from market data by MetaCap's automated system. Methodology
Erasca cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Net Income | -124.55M | -161.65M | -125.04M | -242.81M | -122.76M | -101.66M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| Depreciation & Amortization | 3.11M | 3.81M | 3.73M | 2.64M | 829.00K | 540.00K |
| Stock-Based Compensation | 24.90M | 26.97M | 26.23M | 20.11M | 8.33M | 797.00K |
| Change in Working Capital | 513.00K | -1.53M | -886.00K | 676.00K | 1.34M | -380.00K |
| Operating Cash Flow | -95.45M | -109.42M | -101.22M | -103.26M | -79.60M | -32.69M |
| Capital Expenditures | -128.00K | -60.00K | -1.77M | -14.55M | -11.21M | -947.00K |
| Investing Cash Flow | 100.42M | -156.62M | -91.22M | -71.08M | -64.59M | -71.20M |
| Financing Cash Flow | 1.10M | 240.70M | 1.29M | 98.08M | 439.40M | 139.99M |
| Net Change in Cash | 6.07M | -25.34M | -191.14M | -76.27M | 295.21M | 36.10M |
| Free Cash Flow | -95.58M | -109.48M | -102.99M | -117.81M | -90.81M | -33.63M |
This table shows 6 annual periods of Erasca's cash flow statement, from FY 2025 back to FY 2020, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ERAS's reporting calendar. What is a cash flow statement?